Mayo Clinic launches AI-powered clinical development platform leveraging international partner ecosystem
Mayo Clinic has launched Mayo Clinic Platform_Orchestrate, a comprehensive programme designed to accelerate clinical development by providing biopharma and medical device companies with streamlined access to de-identified clinical data, artificial intelligence tools, and international research networks.
Integrated access to clinical data and expertise
Announced on 2 October 2025, Mayo Clinic Platform_Orchestrate establishes a single entry point for life sciences companies seeking to collaborate with Mayo Clinic’s research infrastructure. The programme removes traditional barriers in clinical development by consolidating access to real-world clinical data, biospecimens, multi-omics profiling capabilities, and physician-scientist expertise within one coordinated framework.
The platform addresses three critical phases of therapeutic development: discovery through real-world clinical data and biospecimens; validation via rigorous testing of AI models and digital solutions; and deployment through scalable infrastructure across Mayo Clinic’s international partner network.
AI-driven analytics and multimodal data integration
Central to the platform’s capabilities is its partnership with nference, which provides access to de-identified, multimodal longitudinal clinical data encompassing over 40 million patient journeys. This data infrastructure enables companies to develop and validate AI models for early disease detection, identify patient populations for targeted therapies, and enhance clinical trial recruitment strategies.
“Mayo Clinic Platform_Orchestrate was created to help our life sciences and biopharma partners bring therapies to patients safely and faster,” says Maneesh Goyal, chief operating officer of Mayo Clinic Platform. “By combining trusted data, advanced AI and Mayo Clinic’s scientific expertise, we are reimagining what’s possible in clinical development.”
Operational framework and partnership model
The programme operates through a structured five-stage process encompassing initial evaluation, programme development, contracting, technical onboarding, and coordinated delivery. This framework aims to streamline traditionally complex collaboration agreements whilst ensuring alignment with Mayo Clinic’s research standards and patient-centred care principles.
Early collaborations are already underway with multiple life sciences and technology firms. Current projects include development of multimodal AI models for disease detection, creation of precision patient identification tools, diversification of clinical trial recruitment, and deployment of validated digital health solutions across domestic and international care settings.
Global scale and translational potential
Mayo Clinic Platform_Orchestrate extends beyond Mayo Clinic’s United States facilities, leveraging the institution’s international partner ecosystem to enable global-scale solution deployment. This geographic reach, combined with comprehensive data access and AI infrastructure, positions the platform to support clinical development programmes across multiple therapeutic areas.
The platform’s multi-omics capabilities and biospecimen resources provide additional depth for discovery-stage research, whilst its validation infrastructure supports the refinement of digital health technologies before clinical implementation.
By consolidating previously disparate resources into a coordinated programme, Mayo Clinic Platform_Orchestrate represents a structural approach to reducing development timelines for novel therapeutics whilst maintaining rigorous validation standards. The platform’s emphasis on real-world evidence generation and AI-enabled insights reflects broader trends towards data-driven clinical development strategies in pharmaceutical research.
-
Interested to join the Mayo Clinic Platform_Orchestrate?
Contact Mayo Clinic for more information here:
https://info.mayoclinicplatform.org/contact
